

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of the claims:

1. (Original) A method of protecting a patient from possible adverse effects of a treatment involving inhibition of the SHH-signalling pathway in the patient, the method comprising suppressing testosterone or its effect in the patient.

2. (Currently amended) A method of treating a proliferative disease ~~such as cancer~~ in a patient the method comprising inhibiting the SHH-signalling pathway and suppressing testosterone or its effect in the patient.

3. (Currently amended) A method according to Claim ~~1 or~~ 2 wherein the SHH-signalling pathway is inhibited by the administration of cyclopamine or a derivative thereof to the patient.

4. (Currently amended) A method according to ~~any one of the preceding claim~~ Claim 2 wherein testosterone is suppressed to castrate levels.

5. (Currently amended) A method according to ~~any one of the preceding claims~~ Claim 2 wherein testosterone or its effect is suppressed by administering any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a 5 α reductase inhibitor to the patient.

6. (Currently amended) A method according to ~~any one of the preceding claims~~ Claim 2 wherein the patient is male ~~preferably a post-pubescent male~~.

7. (Currently amended) A method according to ~~any one of Claims 2 to 6~~ Claim 2 wherein the ~~cancer~~ proliferative disease is a cancer in which SHH-signalling plays a role in its growth and/or differentiation.

8. (Currently amended) A method according to ~~any one of Claims 2 to 6~~ Claim 2 wherein the ~~cancer~~ proliferative disease is any of basal cell carcinoma, medulloblastoma, glioblastoma or prostate cancer.

9-17 (Canceled)

18. (Original) A therapeutic system for treating a patient, the system comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in the patient.

19. (Original) A composition comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in a patient.

20. (Canceled)

21. (Original) A pharmaceutical composition comprising an inhibitor of the SHH-signalling pathway and a compound which suppresses testosterone or its effect in a patient and a pharmaceutically acceptable carrier.

22-23 (Canceled)

24. (New) A method according to Claim 1 wherein the SHH-signalling pathway is inhibited by the administration of cyclopamine or a derivative thereof to the patient.

25. (New) A method according to Claim 1 wherein testosterone is suppressed to castrate levels.

26. (New) A method according to Claim 1 wherein testosterone or its effect is suppressed by administering any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a 5α reductase inhibitor to the patient.

27. (New) A method according to Claim 1 wherein the patient is male.

28. (New) A method according to Claim 1 wherein the treatment is for a cancer in which SHH-signalling plays a role in its growth and/or differentiation.

29. (New) A method according to Claim 1 wherein the treatment is for any of basal cell carcinoma, medulloblastoma, glioblastoma, or prostate cancer.